If you had offered up on cannabis stocks, let me inform you why you ought to reconsider this year.
Revenue skyrocketed in Q1
GW Pharmaceuticals is the maker of Epidiolex, a prescription drug consisting of cannabidiol, or CBD, for the treatment of seizures related to Lennox-Gastaut syndrome or Dravet syndrome. The business’s revenue was up threefold in the first quarter of financial 2020, to $1206 million from $392 million in the year-ago period; this was also up from $1091 million in the fourth quarter of financial2019 The outcomes were thanks to rising Epidiolex global sales, which can be found in at $1161 million for the quarter. U.S. sales alone were $1061 million, demonstrating the brand’s big consumer base.
IMAGE SOURCE: GETTY IMAGES.
U.S. marijuana business consisting of Green Thumb Industries( OTC: GTBI.F), Curaleaf Holdings( OTC: CURL.F), and Cresco Labs ( OTC: CRLB.F) also saw revenue increase threefold in their current quarters. Green Thumb’s and Curaleaf’s first-quarter revenue increased 268%and 174%, respectively, year-over-year, while Cresco Labs saw a 215%rise.
It’s simply not the income numbers that are appealing– GW likewise has a strong balance sheet. It ended the very first quarter with money and cash equivalents of $5009 million.
Capturing the market with Epidiolex
Epidiolex sales might even more increase in 2020 as GW aims to improve access to the drug for clients in the U.S. and Europe. The recent descheduling of Epidiolex in the U.S. by the Drug Enforcement Administration (DEA) will help increase patient base. The CBD in Epidiolex is stemmed from marijuana, not hemp, which implies it’s still federally prohibited in the U.S.– hemp is now legal, but marijuana is not. The descheduling of Epidiolex relocations it from Schedule I drug status (amongst the most dangerous) to Set up V (the least limiting) under the federal Controlled Substances Act (CSA), making it easier for patients to access it in the U.S.
GW said brand-new client prescriptions were consistent in the quarter, as was the retention of previous patients– illustrating the strength of the brand in the middle of COVID-19
As the continuous increase in medical cannabis demand in the U.S. and globally demonstrates, a growing number of individuals are starting to comprehend the benefits of medical marijuana over traditional medicines. As management said on the earnings call, ” Looking ahead, GW is well placed to emerge highly from the COVID-19 crisis with substantial growth prospects for Epidiolex in the U.S. and Europe, important pipeline clinical trials prepared to perform, a strong balance sheet, and an unrivaled leading position in cannabinoid science.”
As I see it, the demand for medical marijuana won’t be taking a hit anytime soon– in reality, if estimates are right, it might see a more rise. Information from market research business IMARC Group recommends the international medical cannabis market could touch $444 billion by 2024, from $134 billion in2018
Concentrate on research and advancement
GW Pharmaceuticals’ research study and advancement (R&D) expenses in Q1 mostly went toward its continuous advancement program for Epidiolex, the improvement of scientific trials for nabiximols (a cannabinoid mouth spray), and its other pipeline programs. R&D was up $155 million from the previous year to $459 million.
The ongoing work on Epidiolex in the U.S. and the development of commercial operations in Europe also enhanced GW Pharmaceuticals’ selling, basic, and administrative (SG&A) expenses to $712 million from $551 million in Q12019 Despite the increase in expenses, the business handled to reduce its bottom lines dramatically– to $8 million in the quarter from $501 million a year ago.
Management hopes that their R&D and SG&An expenses for 2020 will can be found in below guidance of $530 million to $560 million, with capital investment varying from $30 million to $40 million. Management also noted that it’s tough to figure out the specific result of the coronavirus pandemic on the company, given the unpredictability.
Attempt to sustain and thrive
Amidst the pandemic, the most concerning thing for business in a progressing market like cannabis is to make certain they hold adequate money to endure the crisis and keep business running. The ones with a strong balance sheet might be able to not just last longer than the chaos but prosper as soon as the pandemic retreats. Certainly, in May, shares of GW Pharmaceuticals and Green Thumb were up 33%and 50%, respectively, compared with the SPDR S&P 500 ETF‘ s( NYSEMKT: SPY) gain of 7.6%.
Looking at GW Pharmaceuticals’ strong earnings growth, its growth plans, and its solid balance sheet provides me self-confidence in this marijuana stock for2020
Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Green Thumb Industries. The Motley Fool has a disclosure policy.”> Sushree Mohanty has no position in any of the stocks discussed. The Motley Fool owns shares of and advises Cresco Labs Inc. and Green Thumb Industries. The Motley Fool has a disclosure policy“>